{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:43:38Z","timestamp":1773243818157,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CONACYT (Consejo Nacional de Ciencia y Tecnolog\u00eda) of Mexico","award":["CONACYT FMSLP-2002-5585"],"award-info":[{"award-number":["CONACYT FMSLP-2002-5585"]}]},{"name":"Universidad Aut\u00f3noma de San Luis Potos\u00ed, M\u00e9xico","award":["C07-FAI-11-24.60 Ref: 16\/2007"],"award-info":[{"award-number":["C07-FAI-11-24.60 Ref: 16\/2007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to compare the pharmacokinetics (PK) of rifampicin (RIF) between healthy volunteers and patients with tuberculosis (TB).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RIF was administered as a single 600-mg dose to 24 healthy volunteers and 24 TB patients, followed by serial blood sampling. Plasma concentrations were analysed using a chromatographic method, and the PK parameters were estimated using WinNonlin software.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Peak plasma concentration ranged from 6.4 to 19.9 mg\/l, which was subtherapeutic for 15% of the study participants in both groups, mostly in men (71.4%). The mean area under the concentration-time curve (AUC0\u201324h) did not show differences between these groups (P &amp;gt; 0.05). The absorption rate was slower in TB patients and the volume of distribution normalized by total body weight (Vd\/kg) was greater than healthy volunteers (P &amp;lt; 0.05). A greater Vd and clearance were found in male subjects. The lag time (tlag) and the time before reach Cmax (Tmax) were longer for female TB patients (P &amp;lt; 0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The main differences in PK parameters of RIF between Mexican TB patients and healthy volunteers were demonstrated in absorption and distribution processes. In addition, differences in PK parameters observed by sex should be considered for further dosing recommendations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12275","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T06:51:28Z","timestamp":1400568688000},"page":"1421-1428","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers"],"prefix":"10.1093","volume":"66","author":[{"given":"Susanna E","family":"Medell\u00edn-Garibay","sequence":"first","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, UASLP , San Luis Potos\u00ed, SLP,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, UASLP , San Luis Potos\u00ed, SLP,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Maga\u00f1a-Aquino","sequence":"additional","affiliation":[{"name":"Hospital Central \u2018Dr. Ignacio Morones Prieto\u2019 , San Luis Potos\u00ed, SLP,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Patricia","family":"Portales-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, UASLP , San Luis Potos\u00ed, SLP,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-3745","authenticated-orcid":false,"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, UASLP , San Luis Potos\u00ed, SLP,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"2024103109153768600_jphp12275-cit-0001","volume-title":"Global tuberculosis control","author":"World Health Organization (WHO)","year":"2013"},{"key":"2024103109153768600_jphp12275-cit-0002","volume-title":"Tuberculosis country profiles","author":"World Health Organization (WHO)","year":"2013"},{"key":"2024103109153768600_jphp12275-cit-0003","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14656560802694564","article-title":"Tuberculosis pharmacotherapy: strategies to optimize patient care","volume":"3","author":"Mitnick","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2024103109153768600_jphp12275-cit-0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/dkh377","article-title":"Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?","volume":"3","author":"Di Perri","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2024103109153768600_jphp12275-cit-0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4269\/ajtmh.2009.81.322","article-title":"Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis","volume":"2","author":"Barroso","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2024103109153768600_jphp12275-cit-0006","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"8","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"2024103109153768600_jphp12275-cit-0007","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1378\/chest.113.5.1178","article-title":"Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients","volume":"5","author":"Kimerling","year":"1998","journal-title":"Chest"},{"key":"2024103109153768600_jphp12275-cit-0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1413-86702006000600003","article-title":"Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis","volume":"6","author":"Pinheiro","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"2024103109153768600_jphp12275-cit-0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/S1413-86702009000300011","article-title":"Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis","volume":"3","author":"Facanha","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"2024103109153768600_jphp12275-cit-0010","first-page":"1454","article-title":"Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation","volume":"11","author":"Milan-Segovia","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103109153768600_jphp12275-cit-0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2011\/307150","article-title":"Therapeutic drug monitoring in the treatment of active tuberculosis","volume":"4","author":"Babalik","year":"2011","journal-title":"Can Respir J"},{"key":"2024103109153768600_jphp12275-cit-0012","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.29.12.1468","article-title":"Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists","volume":"12","author":"Hall","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2024103109153768600_jphp12275-cit-0013","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"9","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2024103109153768600_jphp12275-cit-0014","volume-title":"NOM-006-SSA2-2013, Para la prevenci\u00f3n y control de la tuberculosis","author":"NORMA Oficial Mexicana","year":"2013"},{"key":"2024103109153768600_jphp12275-cit-0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"15","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"2024103109153768600_jphp12275-cit-0016","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"4","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103109153768600_jphp12275-cit-0017","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"11","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103109153768600_jphp12275-cit-0018","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis patients","volume":"1","author":"Magis-Escurra","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"2024103109153768600_jphp12275-cit-0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1086\/380795","article-title":"Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis","volume":"2","author":"Gurumurthy","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024103109153768600_jphp12275-cit-0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"1","author":"Peloquin","year":"1999","journal-title":"Chest"},{"key":"2024103109153768600_jphp12275-cit-0021","first-page":"70","article-title":"Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers","volume":"1","author":"Pargal","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103109153768600_jphp12275-cit-0022","volume-title":"USL RIFATER (R) Prescribing Information","author":"Sanofi-Aventis","year":"2013"},{"key":"2024103109153768600_jphp12275-cit-0023","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"6","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103109153768600_jphp12275-cit-0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0378-5173(01)00754-2","article-title":"A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem","volume":"1\u20132","author":"Singh","year":"2001","journal-title":"Int J Pharm"},{"key":"2024103109153768600_jphp12275-cit-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.11.031","article-title":"Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin","volume":"1\u20132","author":"Panchagnula","year":"2004","journal-title":"Int J Pharm"},{"key":"2024103109153768600_jphp12275-cit-0026","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jps.21624","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: rifampicin","volume":"7","author":"Becker","year":"2009","journal-title":"J Pharm Sci"},{"key":"2024103109153768600_jphp12275-cit-0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","article-title":"The influence of sex on pharmacokinetics","volume":"2","author":"Schwartz","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2024103109153768600_jphp12275-cit-0028","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"3","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2024103109153768600_jphp12275-cit-0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-642-30726-3_5","article-title":"Sex differences in drug effects: interaction with sex hormones in adult life","volume":"214","author":"Spoletini","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"2024103109153768600_jphp12275-cit-0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/bdd.464","article-title":"Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms","volume":"8","author":"Agrawal","year":"2005","journal-title":"Biopharm Drug Dispos"},{"key":"2024103109153768600_jphp12275-cit-0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"2","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"key":"2024103109153768600_jphp12275-cit-0032","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00044011-200323070-00005","article-title":"Serum rifampicin levels in patients with tuberculosis: effect of P-Glycoprotein and CYP3A4 blockers on its absorption","volume":"7","author":"Prakash","year":"2003","journal-title":"Clin Drug Investig"},{"key":"2024103109153768600_jphp12275-cit-0033","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"10","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103109153768600_jphp12275-cit-0034","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/004982597239994","article-title":"Rifampin and rifabutin and their metabolism by human liver esterases","volume":"10","author":"Jamis-Dow","year":"1997","journal-title":"Xenobiotica"},{"key":"2024103109153768600_jphp12275-cit-0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jcpt.12016","article-title":"Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis","volume":"1","author":"Milan Segovia","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2024103109153768600_jphp12275-cit-0036","first-page":"972","article-title":"Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels","volume":"9","author":"Um","year":"2007","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12275","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/10\/1421\/60251910\/jphp12275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/66\/10\/1421\/60251910\/jphp12275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:19:50Z","timestamp":1730366390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/66\/10\/1421\/6128018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12275","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,10,1]]}}}